Not available
Quote | Biogen Inc. (NASDAQ:BIIB)
Last: | $211.17 |
---|---|
Change Percent: | 7.06% |
Open: | $211.38 |
Close: | $211.17 |
High: | $217.53 |
Low: | $210 |
Volume: | 2,206,673 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Biogen Inc. (NASDAQ:BIIB)
2024-07-26 11:48:00 ET Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032...
2024-07-26 11:18:45 ET More on AbbVie AbbVie Inc. (ABBV) Q2 2024 Earnings Call Transcript AbbVie: Why I Sold My Shares At $175 AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note Cerevel gains as AbbVie says it expects deal to close ...
Message Board Posts | Biogen Inc. (NASDAQ:BIIB)
Subject | By | Source | When |
---|---|---|---|
Oops. Another HOD $10 | Lonewolf1 | investorshub | 03/29/2023 1:43:04 PM |
$BIIB Took a little short AH when it's | MiamiGent | investorshub | 03/23/2023 2:13:35 AM |
FDA Accepts Eisai's Filing of a Supplemental Biologics | Mr. Zen | investorshub | 03/06/2023 2:22:27 AM |
This board is about to light up! | Mr. Zen | investorshub | 03/06/2023 2:21:44 AM |
Well Biib and Esaly look to be joined | tredenwater2 | investorshub | 01/09/2023 11:15:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.06%Change Percent:
Biogen Inc. Company Name:
BIIB Stock Symbol:
NASDAQ Market:
Biogen Inc. Website:
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...